-
John Ternus to lead Apple in the age of AI
-
SpaceX partners with AI startup Cursor, may buy it for $60 bn
-
Mexico pyramid shooter inspired by Columbine attack, pre-Hispanic sacrifices
-
Mexico pyramid shooter planned attack, fixated on US massacre
-
Mbappe on the mark as Real Madrid sink Alaves
-
Rosenior blasts Chelsea flops after 'unacceptable' Brighton defeat
-
Inter roar back to beat Como and reach Italian Cup final
-
Lens sweep past Toulouse to reach French Cup final
-
Brighton crush Chelsea to pile pressure on under-fire Rosenior
-
Strait of Hormuz blockade drives up costs at Panama Canal
-
Trump extends ceasefire, says giving Iran time to negotiate
-
Michelle Bachelet hopes the world is ready for a female UN chief
-
Nowitzki, Bird among eight inductees into FIBA Hall of Fame
-
Stocks fall, oil climbs amid uncertainty over US-Iran talks
-
Iran war means more orders for US defense giants
-
Mexico pyramid shooting was planned attack, officials say
-
Trump's messaging on Iran grows increasingly erratic
-
Churchill Downs buys Preakness for $85 million
-
Unregulated AI like speeding with no steering wheel: AI godfather Hinton
-
Tourists return to Rio viewpoint after shootout scare
-
Maradona's daughter slams 'manipulation' of family by his doctors
-
Abhishek's 135 powers Hyderabad to third straight IPL win
-
Vance still in Washington as uncertainty mounts over US-Iran talks
-
No.1 Jeeno seeks first major win at LPGA Chevron event
-
New batch of World Cup tickets to go on sale
-
Material girl: Madonna offers reward for missing clothes
-
Maker of Argentina's first Oscar-winning film, Luis Puenzo, dies at 80:
-
Rape retrial hears Weinstein 'preyed' on aspiring US actress
-
Arrests, hangings, blackout: Iran cranks up wartime repression
-
Seixas relishes 'steep' challenge at Fleche Wallonne
-
US Fed chair nominee says will not be controlled by Trump
-
Singapore's Tang gets second term at UN's patent agency
-
Taiwan leader postpones Eswatini trip after overflight permits revoked
-
Lula warns will respond after US expels police attache
-
Trailblazer Karren Brady steps down from West Ham role
-
US Fed chair nominee says he will not be controlled by Trump
-
In Portugal, Lula urges return to multilateralism
-
Sinner wants to use Madrid to boost career Grand Slam chances
-
Renewables key to buffer fossil fuel energy shock: COP31 co-hosts
-
Chery wants to make small electric car in Europe
-
Donovan steps down as Bulls coach
-
US official says gas prices have peaked despite Iran war
-
Pope calls for 'law and justice' on Equatorial Guinea visit
-
Trump's Fed chair pick vows to safeguard independence at confirmation hearing
-
Mideast war lights fire under energy transition plans
-
Djibouti president re-election confirmed with 97% of vote
-
Barcelona need leaders to fulfil Flick's Champions League dream
-
Guardiola hints that Rodri will make swift Man City return
-
'We weren't soft, we were skilled': Nowitzki on NBA's European revolution
-
PSG and Luis Enrique sweat on Vitinha ahead of Champions League semis
Water Tower Research Highlights Ainos' SmellTech Platform AI Nose as Foundational AI Innovation
AI Nose delivers accuracy and versatility, driving scalable growth across healthcare, industrial and robotics markets
Technology, data moat, and strategic partnerships position Ainos for accelerated commercial readiness and expansion
SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research has published a recap of its recent Small-Cap Spotlight podcast. The report highlights the Company's AI Nose platform, an advanced smell digitization technology powered by artificial intelligence and built on over a decade of innovation, a deep data moat, strategic partnerships, and a clear commercialization roadmap. The report identifies AI Nose as a foundational innovation in olfactory AI, a rapidly emerging and underdeveloped frontier within the sensory AI landscape.
Key Highlights from the Report:
AI Nose establishes olfactory AI as a powerful new tool for industrial intelligence, combining accuracy with adaptability: AI Nose delivers 90+% accuracy in distinguishing everyday scents, 85% in senior care environments, and 80% across 22 industrial scent types in semiconductor settings. Its AI model, smell language model (SLM), improves with each use, creating a powerful data-driven flywheel effect that can support scalable deployment across multiple high-growth verticals.
Early-mover innovation and data moat cement AI Nose's distinct competitive edge in smell digitization: While most AI innovation has focused on vision and voice, Ainos positions smell as a high-impact, underdeveloped frontier. Built on over a decade of technical innovation and a growing scent dataset, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays into a powerful scent sensing platform. Originally developed for medical use, the platform has expanded into robotics, semiconductor manufacturing, and industrial automation, positioning it as a frontrunner in the fast-emerging field of olfactory AI.
Strategic partnerships fuel commercial scale-up across key verticals: Ainos is rapidly expanding AI Nose's market reach and accelerating commercialization through strategic alliances - with more likely to come. The Company sees Asia as a key launchpad given the region's strengths in electronic manufacturing services, semiconductors, automation and robotics. At the same time, Ainos welcomes partnership opportunities in the U.S. and Europe to support global commercialization.
Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_07202025
Those interested can listen to the full podcast via Apple Podcasts, Spotify, or Water Tower Research's website.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
[email protected]
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN